8-KOther Events

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Aug 22, 2011)

Filed August 22, 2011For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) announced on August 22, 2011, a significant regulatory milestone: Health Canada has approved INCIVEK™ (telaprevir) tablets. This approval marks a crucial step in expanding access to Vertex's groundbreaking treatment for chronic hepatitis C. The approval is for a broad patient population with genotype 1 chronic hepatitis C and compensated liver disease, including those with cirrhosis. INCIVEK will be used in combination with pegylated-interferon and ribavirin, addressing both treatment-naïve patients and those who have previously undergone treatment without achieving a sustained viral response. This includes key subgroups such as relapsers, partial responders, and null responders, indicating a comprehensive approach to tackling treatment failures in hepatitis C.

Key Highlights

  • 1Health Canada has approved INCIVEK™ (telaprevir) tablets.
  • 2The approval is for genotype 1 chronic hepatitis C patients with compensated liver disease, including cirrhosis.
  • 3INCIVEK™ is approved for use in combination with pegylated-interferon and ribavirin.
  • 4The drug is indicated for treatment-naïve patients.
  • 5The approval also covers patients who previously received treatment but did not achieve a sustained viral response.
  • 6Specifically included are relapsers, partial responders, and null responders, addressing diverse treatment failure scenarios.

Frequently Asked Questions

The Health Canada approval signifies a major regulatory clearance for Vertex Pharmaceuticals' INCIVEK™ (telaprevir) for the treatment of chronic hepatitis C. This allows the company to market and sell the drug in Canada, expanding its global reach and potential revenue.

INCIVEK™ is approved for a broad range of patients with genotype 1 chronic hepatitis C who have compensated liver disease, including those with cirrhosis. This includes individuals who are new to treatment and those who have previously been treated but did not achieve a sustained viral response, covering relapsers, partial responders, and null responders.

INCIVEK™ is approved for use in combination with two other standard hepatitis C medications: pegylated-interferon and ribavirin.

This specific 8-K filing only reports the approval by Health Canada. Approvals in other jurisdictions, such as the United States or Europe, would be announced separately.